International Edition
Latest News
Technology

Viscoelasticity Reprograms T Cell Metabolism for TCR-T Cell Manufacturing and Therapy

Researchers at UCLA and USC have engineered synthetic antigen-presenting cells that mimic the viscoelastic properties of natural immune cells, enabling a manufacturing platform that produces T-cell receptor therapies with enhanced stem-like metabolism and durable anti-tumor activity in solid…

Researchers at UCLA and USC have engineered synthetic antigen-presenting cells that mimic the viscoelastic properties of natural immune cells, enabling a manufacturing platform that produces T-cell receptor therapies with enhanced stem-like metabolism and durable anti-tumor activity in solid tumor models.

The study, published in Nature Biomedical Engineering, introduces synthetic viscoelastic activating cells (SynVAC) whose stress-relaxation kinetics can be chemically tuned independently of stiffness and ligand density. Fast-relaxing SynVAC amplified TCR signaling and mTOR activity, drove mitochondrial remodeling, and programmed antigen-specific CD8+ T cells toward an energetically favorable metabolic state with enhanced stem-like properties, the authors reported.

“Viscoelasticity reprograms T cell metabolism for TCR-T cell manufacturing and therapy,” the research team wrote in the paper, establishing cell-mimetic viscoelasticity as a key biophysical cue governing T cell differentiation.

A mechanical cue overlooked in current manufacturing

Current clinical manufacturing of TCR-T and CAR-T cells typically relies on rigid plastic plates, magnetic beads, or feeder cells that present biochemical signals but lack the dynamic mechanical properties of living antigen-presenting cells. Natural dendritic cells and B cells exhibit stress relaxation — the ability to dissipate mechanical stress over time — a property that static substrates cannot replicate.

The SynVAC platform addresses this gap using a high-throughput microfluidic system to fabricate synthetic cells with precisely tuned viscoelasticity while maintaining constant elastic modulus, pMHC density, and co-stimulatory ligand presentation. This decoupling allowed the researchers to isolate viscoelasticity as an independent variable for the first time.

Fast-relaxing substrates outperform dendritic cells

In head-to-head comparisons, fast-relaxing SynVAC-pMHC enriched antigen-specific CD8+ T cells more effectively than monocyte-derived dendritic cells (moDCs), the current gold-standard cellular APC. The fast-relaxing condition amplified early TCR signaling events and sustained mTOR pathway activation, which the authors linked to mitochondrial remodeling and a metabolic shift toward oxidative phosphorylation.

Metabolic profiling via Seahorse assay showed that CD8+ T cells activated on fast-relaxing SynVAC exhibited higher basal and maximal oxygen consumption rates (OCR) compared to cells on medium-relaxing, slow-relaxing, or IL-2 control conditions. Intracellular metabolite analysis further revealed elevated TCA cycle intermediates and nucleotide pools in the fast-relaxing group, indicating an energetically favorable state supportive of stem-like memory formation.

FLIM-based metabolic imaging confirmed these findings, showing distinct NAD(P)H fluorescence lifetime signatures — specifically increased α-bound fraction and reduced redox ratio — in T cells cultured on fast-relaxing substrates, consistent with enhanced oxidative metabolism and mitochondrial efficiency.

Superior persistence and tumor control in vivo

TCR-T cells expanded using fast-relaxing SynVAC-pMHC demonstrated superior persistence and durable anti-tumor activity in both melanoma and ovarian cancer mouse models. The manufactured cells showed increased stem-like memory markers (TCF-1, LEF-1) and reduced exhaustion markers (TOX, PD-1) compared to counterparts expanded on slow-relaxing or rigid substrates.

In a human ovarian cancer xenograft model, mice treated with fast-relaxing SynVAC-expanded TCR-T cells exhibited significantly reduced tumor burden and prolonged survival. The cells persisted longer in vivo and maintained polyfunctional cytokine production upon re-stimulation.

A parallel study on CAR-T cells using the same SynVAC platform, reported in Nature Biomedical Engineering (2025), showed approximately 90% CAR transduction efficiency and substantial increases in T memory stem cells. Those engineered CAR-T cells eliminated tumor cells in a human lymphoma mouse model and suppressed tumor growth in ovarian cancer xenografts with reduced recurrence risk, according to the PubMed-indexed report.

Patent pending for SynVAC as GMP-compliant manufacturing candidate

The technology is protected by a pending patent application (PCT/US24/22516) filed by inventors Zeyang Liu, Yan-Ruide Li, Lili Yang, and Song Li. The fully synthetic, scalable nature of SynVAC — free of biological variability inherent in dendritic cell or feeder cell preparations — positions it as a candidate for GMP-compliant manufacturing of next-generation TCR-T and CAR-T therapies targeting solid tumors.

The work was supported by the UCLA Jonsson Comprehensive Cancer Center, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the USC Norris Comprehensive Cancer Center, among other institutes.

SynVAC mimics living immune cells with tunable viscoelasticity

What is SynVAC and how does it differ from current T cell activation methods?
SynVAC (synthetic viscoelastic activating cells) are fully synthetic artificial antigen-presenting cells fabricated via microfluidics. Unlike rigid beads or plastic plates, SynVAC mimics the stress-relaxation behavior of living immune cells while allowing precise, independent tuning of viscoelasticity, stiffness, and ligand density.

Why does viscoelasticity matter for T cell therapy manufacturing?
Viscoelasticity is a fundamental mechanical property of natural antigen-presenting cells. The study shows that fast stress relaxation amplifies TCR signaling and mTOR activity, drives mitochondrial remodeling, and programs T cells toward a stem-like metabolic state — features linked to better persistence and anti-tumor efficacy in solid tumor models.

Has this been tested in humans?
Not yet. The reported data are from in vitro human T cell cultures and in vivo mouse models of melanoma, ovarian cancer, and lymphoma. The synthetic, scalable nature of SynVAC is designed to enable GMP translation, but clinical trials have not been announced.

UCLA traces its academic roots to 1881 as the southern branch of the California State Normal School, now San José State University, and became the second campus in the University of California system when it was transferred in 1919.

Today it enrolls roughly 31,600 undergraduate and 14,300 graduate students and received 174,914 undergraduate applications for Fall 2022, the most of any U.S. university. Its faculty and alumni include 19 Nobel laureates and 11 Rhodes scholars as of October 2025.

What intellectual property protects this technology?
A PCT patent application (PCT/US24/22516) has been filed by Zeyang Liu, Yan-Ruide Li, Lili Yang, and Song Li covering SynVAC composition and use.

About the author: Technology Desk

Technology Desk at Archynewsy.